| Literature DB >> 35185808 |
Jing-Jing Ni1,2, Qian Xu1,3, Shan-Shan Yan1,3, Bai-Xue Han1,3, Hong Zhang1,2, Xin-Tong Wei1,3, Gui-Juan Feng1,3, Min Zhao1,2, Yu-Fang Pei1,3, Lei Zhang1,2.
Abstract
Evidence supports the observational associations of gut microbiota with a variety of psychiatric disorders, but the causal nature of such associations remains obscure. Aiming to comprehensively investigate their causal relationship and to identify specific causal microbe taxa for psychiatric diseases, we conducted a two-sample Mendelian randomization (MR) analysis of gut microbiome with 15 psychiatric diseases. Specifically, the microbiome genome-wide association study (GWAS) in 18,473 individuals from the MiBioGen study was used as exposure sample, and the GWAS for 15 psychiatric diseases was used as outcome samples. One-hundred ninety bacterial taxa from six levels were available for analysis. At a multiple-testing corrected significance level (phylum P < 5.56 × 10-3, class P < 3.33 × 10-3, order P < 2.63 × 10-3, family P < 1.67 × 10-3, genus P < 4.90 × 10-4, and species P < 3.33 × 10-3), the following eight causal associations from seven bacterial features (one phylum + three classes + one order + one family + one species) were identified: family Prevotellaceae with autism spectrum disorder (P = 5.31 × 10-4), class Betaproteobacteria with bipolar disorder (P = 1.53 × 10-3), class Actinobacteria with schizophrenia (P = 1.33 × 10-3), class Bacteroidia and order Bacteroidales with Tourette syndrome (P = 2.51 × 10-3 and 2.51 × 10-3), phylum Actinobacteria and class Actinobacteria with extroversion (P = 8.22 × 10-4 and 1.09 × 10-3), and species Clostridium innocuum with neuroticism (P = 8.92 × 10-4). Sensitivity analysis showed no evidence of reverse causality, pleiotropy, and heterogeneity. Our findings offered novel insights into the gut microbiota-mediated development mechanism of psychiatric disorders.Entities:
Keywords: Mendelian randomization (MR); causal relationship; gut microbiota (GM); psychiatric disorders; species Clostridium innocuum
Year: 2022 PMID: 35185808 PMCID: PMC8856606 DOI: 10.3389/fmicb.2021.737197
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
FIGURE 1Diagrammatic description of the whole workflow in MR analysis. A flowchart of the whole MR analysis was displayed in this figure.
Characteristics of included genome-wide association studies for psychiatric disorders.
| Psychiatric disorders/traits | Ethnicity | N | No. SNP | Data type | Genotyping platform and SNP panel | References | Study |
| Depression | European | 500,199 | 8,483,301 | Binary | Affymetrix United Kingdom Biobank/BiLEVE Axiom array, IMPUTE4, HRC and UK10K; PGC Ricopili ( |
| UKB, PGC |
| ADHD | Multi-ancestry | 55,374 | 8,047,421 | Binary | Illumina PsychChip; 1KGP Phase 3; PGC Ricopili |
| iPSYCH, PGC |
| ASD | European | 46,351 | 9,112,386 | Binary | PsychChip array; 1KGP Phase 3; PGC Ricopili |
| iPSYCH, PGC |
| BD | European | 51,710 | 9,372,253 | Binary | PGC Ricopili, 1KGP |
| PGC |
| SCZ | Multi-ancestry | 152,805 | 9,444,230 | Binary | PGC Ricopili, 1KGP |
| PGC |
| AUDIT | European | 121,604 | 16,213,998 | Continuous | Affymetrix United Kingdom Biobank/BiLEVE Axiom array, IMPUTE4, HRC |
| UKB |
| CUD | European | 162,082 | 11,535,592 | Continuous | Affymetrix United Kingdom Biobank/BiLEVE Axiom array, IMPUTE4, HRC; various, 1KGP Phase 1 |
| UKB, ICC |
| AN | European | 72,517 | 82,191,012 | Binary | Affymetrix United Kingdom Biobank/BiLEVE Axiom array, IMPUTE4, HRC; PGC Ricopili, 1KGP Phase 3; various |
| UKB, PGC, ANGI, GCAN/WTCCC3 |
| TS | European | 14,307 | 8,265,318 | Binary | Illumina HumanOmniExpress 8/12v1, IMPUTE v2, 1KGP Phase 1 |
| PGC |
| OCD | Multi-ancestry | 9,725 | 8,409,516 | Binary | Illumina Human610-Quadv1_B, Illumina HumanOmniExpress, IMPUTE2, 1KGP Phase 1 |
| IOCDF-GC, OCGAS |
| Extroversion | European | 63,030 | 6,941,603 | Continuous | Illumina/Affymetrix, IMPUTE, 1KGP Phase 1 |
| GPC |
| NEU | European | 390,278 | 10,849,319 | Continuous | Affymetrix United Kingdom Biobank/BiLEVE Axiom array, HRC and UK10K; Illumina/Affymetrix, IMPUTE, 1KGP Phase 1 |
| UKB, GPC |
| AD | European | 23,809 | 9,029,716 | Binary | Illumina PsychChip, SHAPEIT and IMPUTE2, PGC Ricopili, 1KGP phase 3 |
| iPSYCH |
| SD | European | 29,056 | 8,047,611 | Binary | Illumina PsychChip, SHAPEIT and IMPUTE2, PGC Ricopili, 1KGP phase 3 |
| iPSYCH |
| PTSD | Multi-ancestry | 206,655 | 9,788,621 | Binary | Affymetrix Axiom array; Illumina genotyping arrays, PGC Ricopili, IMPUTE2, 1KGP phase 3 |
| UKB, PGC |
| SA | European | 50,264 | 8,017,027 | Binary | Infinium PsychChip v1.0 array, IMPUTE2, 1KGP phase 3 |
| iPSYCH |
No. SNP is the total number of SNPs released from the summary data of GWAS.
“Various” refers to more details on genotyping platform as described elsewhere previously.
ADHD, attention deficit/hyperactivity disorder; ASD, autism spectrum disorder; BD, bipolar disorder; SCZ, schizophrenia; AUDIT, alcohol use disorder identification test; CUD, cannabis use disorder; AN, anorexia nervosa; TS, Tourette syndrome; OCD, obsessive-compulsive disorder; NEU, neuroticism; AD, anxiety-related disorder; SD, stress-related disorder; PTSD, posttraumatic stress disorder; SA, suicide attempts; HRC, Haplotype Reference Consortium; PGC, Psychiatric Genomics Consortium; Ricopili, Rapid Imputation Consortium Pipeline; UKB, United Kingdom Biobank; 1KGP, 1000 Genomes Project; iPSYCH, Integrative Psychiatric Research; ICC, International Cannabis Consortium; ANGI, Anorexia Nervosa Genetics Initiative GCAN/WTCCC3, Genetic Consortium for Anorexia Nervosa/Wellcome Trust Case Control Consortium-3; IOCDF-GC, International Obsessive Compulsive Disorder Foundation Genetics Collaborative; OCGAS, Collaborative Genetics Association Studies; GPC: Genetics of Personality Consortium.
Causal estimations of gut microbiota on psychiatric disorders in the MR analysis.
| Bacterial taxa (exposure) | Psychiatric disorder/traits (outcome) | No. SNP | R2 | F | IVW | MLE | MR-Egger | WME | MR-PRESSO | |||||
|
|
|
|
|
|
|
|
|
|
| |||||
| Family | ASD | 13 | 2.61% | 37.99 | 0.24 |
| 0.25 |
| 0.15 | 0.55 | 0.25 | 7.81 × 10–3 | 0.24 | 1.84 × 10–3 |
| Class | BD | 16 | 3.39% | 40.45 | 0.20 |
| 0.21 |
| 0.14 | 0.44 | 0.18 | 0.043 | 0.20 |
|
| Class | SCZ | 28 | 5.54% | 38.60 | 0.12 |
| 0.12 |
| 0.20 | 0.18 | 0.10 | 0.06 | 0.12 |
|
| Class | TS | 11 | 2.66% | 45.82 | −0.46 |
| −0.46 |
| −0.40 | 0.25 | −0.45 | 0.03 | –0.46 |
|
| Order | 11 | 2.66% | 45.82 | −0.46 |
| −0.46 | 3.11 × 10–3 | −0.40 | 0.25 | −0.45 | 0.03 | –0.46 |
| |
| Phylum | Extroversion | 23 | 3.36% | 27.86 | −0.08 |
| −0.08 |
| −0.23 | 0.063 | −0.05 | 0.12 | –0.08 |
|
| Class | 28 | 5.41% | 37.68 | −0.07 |
| −0.07 |
| −0.14 | 0.13 | −0.07 | 0.02 | –0.07 |
| |
| Species | NEU | 5 | 1.95% | 73.33 | 0.03 |
| 0.03 |
| 0.04 | 0.43 | 0.03 | 0.03 | 0.03 | 0.02 |
No. SNP is the number of SNPs being used as IVs.
R
F is the value of F statistics to examine the weak instrument bias.
b
s.e. is standard error of estimate coefficient.
Significant P-values were marked in bold after multiple-testing correction [phylum P = 5.56 × 10
IVW, the inverse-variance weighted test; MLE, the maximum likelihood estimator; WME, the weighted median estimator; ADHD, attention deficit/hyperactivity disorder; ASD, autism spectrum disorder; BD, bipolar disorder; SCZ, schizophrenia; OCD, obsessive-compulsive disorder; TS, Tourette syndrome; NEU, neuroticism; SA, suicide attempt.
FIGURE 2Scatter plots of the 5 MR tests in 8 causal associations from 7 bacterial features to 6 psychiatric disorders/traits. SNP effects were plotted into lines for the inverse-variance weighted test (light blue line), MR-Egger regression (green line), weighted median estimator (red line), MR-PRESSO (light green line) and maximum likelihood estimator (blue line). The slope of the line corresponded to the causal estimation.